BULLETIN ON NARCOTICS

Volume XIX, 1967

INDEX

ABBREVIATIONS

APD	*stands for*	Expert Committee on Dependence-producing drugs
COUNCIL	*stands for*	Economic and Social Council
DSB	*stands for*	Drug Supervisory Body
ICPO	*stands for*	International Criminal Police Organization (INTERPOL)
INCB	*stands for*	International Narcotics Control Board
PCNB	*stands for*	Permanent Central Narcotics Board
WHO	*stands for*	World Health Organization

NOTE

References in italics indicate the beginning and the end of the article cited, when it deals in its entirety with the subject under which it is placed.

A

Abstinence, *see* Withdrawal

Acetyldihydrocodeine
Estimated world requirements, No. 1, p. 38

Addiction, addicts
Bibliography, No. 4, p. *41-47*
Hong Kong, No. 2, p. *35-43*
Services for the prevention and treatment of dependence on alcohol and other drugs — 14th report of WHO Expert Committee on Mental Health, No. 3, p. *47-55*
APD
— Their view, No. 1, p. 17, No. 2, p. 7
— 15th report, No. 1, p. 29, 30, 31, 32
Cocaine, cannabis, No. 1, p. 25
Commission on Narcotic Drugs (21st session), No. 2, p. 60, 61
Compared to alcoholism, No. 2, p. 26
Definition, No. 1, p. 33, No. 2, p. 1, 2, 13, 61
Heroin, No. 1, p. 33, 34
Medical, No. 1, p. 34, No. 2, p. 38, 48
Opium, No. 1, p. 23, 24, 26, No. 2, p. 45-49, 60, 61
PCNB report (1966), No. 1, p. 27, 28
Psychotropic substances, No. 1, p. 7, 8, 15, 16, 17, 18, No. 2, p. 13, 14, 15, 16, No. 3, p. 40

Addiction liability
APD (15th report), No. 1, p. 29, 31, 32
Psychotropic substances, No. 1, p. 15, 16, 31

Ahmed, R. Z.
The characteristics of opium users studied at the treatment centres in Lekhapani and North Lakhimpur, Assam, India, No. 2, p. *45-49* (ill.)

Alcohol, alcoholism
Services for the prevention and treatment of dependence on alcohol and other drugs — 14th report of WHO Expert Committee on Mental Health, No. 3, p. *47-55*
Definition of addiction, No. 1, p. 33, No. 2, p. 26
Switzerland, No. 2, p. 28
Treatment, No. 1, p. 8, 9, No. 2, p. 25, 26
Used with barbiturates, No. 2, p. 15

Alcoholics Anonymous (A.A.)
Alcohol problem, No. 3, p. 48, 52, 53

Allobarbital
Poland, No. 3, p. 6
Therapeutic use, No. 2, p. 24

8 N-allyl noroxymorphone
Identification, No. 2, p. 56

Alphaprodine
Estimated world requirements, No. 1, p. 38

Amitriptyline
Classification of psychotropic drugs, No. 2, p. 14

Ammonium hydroxide
Identification of narcotics, No. 2, p. 52, 54, 55

Amobarbital
Therapeutic use, No. 2, p. 24

Amphetamines
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
The road to controls: barbiturates, amphetamines, tranquillizers and hallucinogens, No. 1, p. *15-19*

Classification of psychotropic drugs, No. 1, p. 3
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 61
Identification, No. 2, p. 51, 52, 53, 55, 56
PCNB report (1966), No. 1, p. 27
Poland, No. 3, p. 6

Analgesics
Commission on Narcotic Drugs (21st session), No. 2, p. 60

Anileridine
Estimated world requirements, No. 1, p. 38

Antitussives
Commission on Narcotic Drugs (21st session), No. 2, p. 60

Apparatus
Zeiss and Beckman IR-5 infra-red spectrophotometers
— Cannabis, No. 1, p. 22

Argentina
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Atropine
Identification, No. 2, p. 55, 56

Avico, Ustik
The determination of morphine in opium, No. 4, p. *1-3*

B

Barbital
Classification of psychotropic drugs, No. 2, p. 14
Poland, No. 3, p. 6
Therapeutic use, No. 2, p. 24

Barbiturates
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
The road to controls: barbiturates, amphetamines, tranquillizers and hallucinogens, No. 1, p. *15-19*
Classification of psychotropic drugs, No. 1, p. 2, 3
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 61
Compared to alcohol, No. 3, p. 48
PCNB report (1966) No. 1, p. 27
Poland, No. 3, p. 6

Belgium
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Bella donna
Medicinal plant, No. 1, p. 1

Benzedrine, *see* Amphetamines

Benzene
Identification of narcotics, No. 2, p. 52, 54
Poppy alkaloids manufacture, No. 3, p. 2

Benzomorphan
APD (15th report), No. 1, p. 29
Bibliography, No. 4, p. 40

Benzoquinolizines
Classification of psychotropic drugs, No. 2, p. 13

Benzylmorphine
Estimated world requirements, No. 1, p. 38

Betameprodine
Estimated world requirements, No. 1, p. 38

Betaprodine
Estimated world requirements, No. 1, p. 38

Bolivia
Coca leaf, No. 2, p. 61

Brazil
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Bufotenine
Hallucinogen, No. 2, p. 17

Bulgaria
Opium production, No. 3, p. 1

Butanol
Identification of narcotics, No. 2, p. 52, 53

Butobarbital
Therapeutic use, No. 2, p. 24

Butyrophenones
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 13

C

Campanini, N.
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*

Canada
Alcohol dependence, No. 3, p. 50
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59

Cannabis
Bibliography, No. 4, p. *36*
Hashish consumption in Egypt, with special reference to psychosocial aspects, No. 2, p. *1-12* (ill.)
Studies with the U.N. cannabis reference sample, No. 1, p. *21-22* (ill.)
Commission on Narcotic Drugs (21st session), No. 2, p. 60, 61
Estimated world requirements, No. 1, p. 38
Medical plant, No. 1, p. 1
PCNB report (1966), No. 1, p. 25
Psychopharmacological agent, No. 1, p. 4
United Nations Laboratory, No. 3, p. 7, 12, 13, 14

Cannabis, Resin
Estimated world requirements, No. 1, p. 38

Central Narcotic Information Bureau (CNIB), Cairo
Hashish consumption, No. 2, p. 1, 7

Charas, *see* Cannabis

Chile
Alcohol dependence, No. 3, p. 50, 51

China
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 61
Illicit traffic of opium, No. 2, p. 61

Chloral
Classification of psychotropic drugs, No. 1, p. 2, No. 2, p. 13

Chlordiazepoxide
Classification of psychotropic drugs, No. 2, p. 13, 16
Therapeutic use, No. 2, p. 26

Chlorpromazine
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 13, 15
Poland, No. 3, p. 6

Coca leaf
Bibliography, No. 4, p. *34-35*
Psychological deficit in chewers of coca leaf, No. 4, p. *11-18*
APD (15th report), No. 1, p. 29
Commission on Narcotic Drugs (21st session), No. 2, p. 61
Estimated world requirements, No. 1, p. 38
Medicinal plant, No. 1, p. 1
PCNB report (1966), No. 1, p. 26

Cocaine
Bibliography, No. 4, p. *34-35*
APD (15th report), No. 1, p. 29
Commission on Narcotic Drugs (21st session), No. 2, p. 61
Compared to LSD, No. 2, p. 28
Egypt, No. 2, p. 1, 2
Estimated world requirements, No. 1, p. 38
Identification, No. 2, p. 51, 52, 55, 56
PCNB report (1966), No. 1, p. 24, 25, 26
Poland, No. 3, p. 5

Cocaism
Psychological deficit in chewers of coca leaf, No. 4, p. *11-18*
APD (15th report), No. 1, p. 29
Commission on Narcotic Drugs (21st session), No. 2, p. 61

Codeine
Bibliography, No. 4, p. 29, 30, 31
Commission on Narcotic Drugs (21st session), No. 2, p. 60
Estimated world requirements, No. 1, p. 38
Identification, determination, No. 2, p. 51, 52, 53, 54, 55, 56, 57, No. 4, p. 2, 3
Obtained from poppy, No. 3, p. 1, 2, 4
PCNB report (1966), No. 1, p. 25, 26, 27, 28

Codeine hydrochloride
Poland, No. 3, p. 1, 5

Codeine-N-Oxide
Estimated world requirements, No. 1, p. 38

Commission on Narcotic Drugs
Twenty-first session, No. 2, p. *59-61* (ill.)
APD (15th report), No. 1, p. 31
PCNB report (1966), No. 1, p. 23, 26
Psychotropic substances
— LSD, No. 1, p. 7, 15
— 10th and 11th sessions, No. 1, p. 15, 16
— 12th and 17th sessions, No. 1, p. 15, 16
— 18th and 19th sessions, No. 1, p. 15, 16, 17
— 21st session, No. 1, p. 18, 19
United Nations Laboratory, No. 3, p. 7, 8, 12, 14

Commissions, *see* Committees

Committees, Commissions
Dunlop Committee, United Kingdom, No. 2, p. 30
Hong Kong Narcotics Advisory Committee, No. 2, p. 35, 38, 39
Interdepartmental Committee on Drug Addiction, Great Britain, No. 2, p. 2, 36
Kielholz Commission, Switzerland, No. 2, p. 32, 33
League of Nations' Advisory Committee on the Traffic in Opium and Other Dangerous Drugs, No. 1, p. 25

Special Committee of Commission on Narcotic Drugs, No. 1, p. 7, 15, 17, 18, 19

Conferences
Conference on Narcotic and Drug Abuse, No. 1, p. 33
Plenipotentiary Conference for the Adoption of a Single Convention, No. 1, p. 16

Consumption
Hashish consumption in Egypt, with special reference to psychosocial aspects, No. 2, p. *1-12* (ill.)
Cocaine, No. 1, p. 24
Codeine, No. 1, p. 25
Control
— Psychotropic substances, No. 1, p. 19, 27
Hong Kong, No. 2, p. 35
Opium, No. 1, p. 23, 24, 26, No. 2, p. 8, 47, No. 4, p. 7, 8
PCNB report (1966), No. 1, p. 25, 26, 27
Psychotropic substances, No. 1, p. 7, 10, 15, 27, No. 2, p. 15, 18, 19, 20, 21, 22, 23, 24, 33

Control, limitation
APD (15th report), No. 1, p. *29-32*
Commission on Narcotic Drugs (21st session), No. 2, p. *59-61* (ill.)
PCNB report (1966), No. 1, p. *23-28*
Some aspects of the production, turnover and control of narcotic drugs in Poland, No. 3, p. *1-6*
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
The road to controls: barbiturates, amphetamines, tranquillizers and hallucinogens, No. 1, p. *15-19*
The United Nations Narcotics Laboratory, No. 3, p. *7-15* (ill.)
Alcohol, No. 3, p. 48, 49, 50, 55
LSD, No. 1, p. 7, 12

Convention, single
DSB's estimated world requirements, No. 1, p. *37-39*
Coca leaf, No. 1, p. 26
Commission on Narcotic Drugs (21st session), No. 2, p. 60
Hallucinogens, No. 1, p. 18
Opium, No. 1, p. 27, 37
PCNB report (1966), No. 1, p. 23, 24, 26, 27
Stimulants, sedatives, No. 1, p. 15, 16, 18

1912 Convention
PCNB report (1966), No. 1, p. 23

1925 Convention
PCNB report (1966), No. 1, p. 25

1931 Convention
DSB's estimated world requirements, No. 1, p. *37-39*
Opium, No. 1, p. 37
PCNB report (1966), No. 1, p. 25

Council (Economic and Social Council)
Forty-second session, No. 2, p. *59-61* (ill.)
PCNB report (1966), No. 1, p. 23
Psychotropic drugs, No. 1, p. 17, 19
United Nations Laboratory, No. 3, p. 7, 8, 14

Cultivation
Coca leaf, No. 1, p. 26, No. 2, p. 61
Hashish, No. 2, p. 1, 60, 61
Opium poppy, No. 1, p. 26, 27, 28, No. 2, p. 60, No. 3, p. 1, 2, 3, 18, 26, 31, 36, 37

Cyclazocine
Identification, No. 2, p. 51, 52, 55, 56
Treatment of heroin addicts, No. 1, p. 30

Cyclobarbital
Poland, No. 3, p. 6
Therapeutic use, No. 2, p. 24

D

Dagga, *see* Cannabis

Darvon, *see* D-propoxyphene

Delay, Jean
Psychopharmacology and psychiatry — Towards a classification of psychotropic drugs, No. 1, p. *1-5*

Delong, Tadeusz; Irena Egierszdorff &
Some aspects of the production, turnover and control of narcotic drugs in Poland, No. 3, p. *1-6*

Demerol, *see* Pethidine

Denmark
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Dependence, *see* Addiction

Desomorphine
Estimated world requirements, No. 1, p. 38

Determination, Assay, Identification, Titration
LSD analysis in seizures, No. 3, p. *39-45* (ill.)
Manual for the determination of narcotics and dangerous drugs in the urine, No. 2, p. *51-57* (ill.)
The determination of morphine in opium, No. 4, p. *1-3*
Cannabis, No. 3, p. 12, 13, 14
Morphine, No. 3, p. 3, 4
Origin of heroin, No. 3, p. 14
Origin of opium, No. 3, p. 7, 8, 9, 10, 11

Dextromoramide
Estimated world requirements, No. 1, p. 38
Poland, No. 3, p. 5

Diacetylmorphine
Abuse, No. 3, p. 50
APD (15th report), No. 1, p. 30
Bibliography, No. 4, p. 29, 30, 31
"Chasing the dragon", No. 2, p. 35
Commission on Narcotic Drugs (21st session), No. 2, p. 61
Egypt, No. 2, p. 1, 2
Estimated world requirements, No. 1, p. 39
Hong Kong, No. 2, p. 35, 39, 40, 42
Identification of morphine, No. 2, p. 51, 52, 53, 55, 56
PCNB report (1966), No. 1, p. 24, 25, 26
United Nations Laboratory, No. 3, p. 7, 14

Diakodion
History of the poppy, No. 3, p. 22

Dial
Therapeutic use, No. 2, p. 24

Dicodid, *see* Dihydrocodeinone

Diethylbarbituric acid, *see* Barbital

Diethylthiambutene
Estimated world requirements, No. 1, p. 38

Dihydrocodeine
Estimated world requirements, No. 1, p. 38
Obtained from poppy, No. 3, p. 1, 4

Dihydrocodeinone
Identification, No. 2, p. 51, 52, 55, 56

Dihydrohydroxymorphinone
Identification, No. 2, p. 55, 56

Dihydromorphine
Bibliography, No. 4, p. 30
Estimated world requirements, No. 1, p. 38

Dihydromorphinone
Identification, No. 2, p. 51, 52, 55, 56

Dilaudid, *see* Dihydromorphinone

Dimethylthiambutene
Estimated world requirements, No. 1, p. 38

Dioxane
Identification of narcotics, No. 2, p. 52, 54

Diphenoxylate
Estimated world requirements, No. 1, p. 38

Dipipanone
Estimated world requirements, No. 1, p. 38

Ditran
Classification of psychotropic drugs, No. 1, p. 3

Dolophine, *see* Methadone

Drug Supervisory Body (DSB)
Commission on Narcotic Drugs (21st session), No. 2, p. 60
PCNB report (1966), No. 1, p. 24

E

Ecgonine
Estimated world requirements, No. 1, p. 38

Ecgonine Methyl Ester
Estimated world requirements, No. 1, p. 38

Egierszdorff, Irena & Tadeusz Delong
Some aspects of the production, turnover and control of narcotic drugs in Poland, No. 3, p. *1-6*

Egypt, *see* United Arab Republic

Ethanol
Identification of narcotics, No. 2, p. 52
Manufacture of poppy alkaloids, No. 3, p. 2

Ethotrimeprazine, *see* Ditran

Ethylalcohol
Compared to LSD, No. 2, p. 28

Ethylmethylthiambutene
Estimated world requirements, No. 1, p. 38

Ethylmorphine
Estimated world requirements, No. 1, p. 39
Obtained from poppy, No. 3, p. 1, 4

Etoxeridine
Estimated world requirements, No. 1, p. 39

Euphorbia paralias
History of poppy, No. 3, p. 22

Expert Committee on Addiction-producing Drugs, *see* WHO-APD (Expert Committee on)

Expert Committee on Dependence-producing Drugs, *see* WHO-APD (Expert Committee on)

Expert Committee on Drugs Liable to Produce Addiction, *see* WHO-APD (Expert Committee on)

Exports
Cannabis, No. 2, p. 61
Cocaine, No. 1, p. 25
Control
— LSD, No. 1, p. 7, 18, 19, No. 2, p. 59
— Sedatives, stimulants, No. 1, p. 16, 18
Morphine, heroin, No. 1, p. 25
Opium, No. 1, p. 26
Poland, No. 3, p. 5
Poppy seed and straw concentrate, No 3, p. 2, 5
Switzerland, No. 2, p. 32

F

Federal Bureau of Narcotics, United States
Legislation, No. 1, p. 33

Fentanyl
Estimated world requirements, No. 1, p. 39

Food and Drug Administration (FDA), United States
Drug control, No. 2, p. 30

France
Alcohol dependence, No. 3, p. 50, 51
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59
Drug control, No. 2, p. 30

G

Ganja, *see* Cannabis

Germany, Federal Republic of
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59

Ghana
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Glaucium luteum
History of poppy, No. 3, p. 21

Glue sniffing
Bibliography, No. 4, p. 48

Gratiola officinalis
History of poppy, No. 3, p. 21

Greece
History of opium and poppy, No. 3, p. 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35

Gutierrez Noriega, C.
Longer-term effects of coca leaf, No. 4, p. 11, 12, 17

H

Habituation, *see* Addiction

Hallucinogens
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
The road to controls: barbiturates, amphetamines, tranquillizers and hallucinogens, No. 1, p. *15-19*
Classification of psychotropic drugs, No. 1, p. 2, 3, 4, 18
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 61
LSD, No. 1, p. 10, 18, 19, No. 3, p. 39, 40

Hashish, *see* Cannabis

Heptobarbital
Therapeutic use, No. 2, p. 24

Heroin, *see* Diacetylmorphine

Hexobarbital
Therapeutic use, No. 2, p. 24

Hine, C. H.; K. Parker &
Manual for the determination of narcotics and dangerous drugs in the urine, No. 2, p. *51-57* (ill.)

Hong Kong
Lessons from the Anti-Narcotic Voluntary Treatment Programme in Hong Kong, No. 2, p. *35-43* (ill.)
Illicit traffic of opium, No. 2, p. 61

Hospitals, treatment centres
Hong Kong
— Castle Peak Addiction Treatment Centre, No. 2, p. 37, 38, 39, 40, 41, 42
— Hong Kong Psychiatric Centre, No. 2, p. 38
— Shek Kwu Chau Treatment Centre, No. 2, p. 41, 42
India
— Opium Addicts Treatment Centres, Assam, No. 2, p. 46, 47, 48, 49
United States
— Lexington Public Health Service Hospital for Drug Addicts, No. 2, p. 37
— Synanon Houses, No. 2, p. 43

Hungary
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Hydrazines
Classification of psychotropic drugs, No. 1, p. 3, No. 2, p. 14, 16, 26

Hydrochloric acid
Identification of narcotics, No. 2, p. 51, 52

Hydrocodone
Estimated world requirements, No. 1, p. 39
Poland, No. 3, p. 5

Hydromorphone
Estimated world requirements, No. 1, p. 39

Hydroxyzine
Classification of psychotropic drugs, No. 2, p. 13
Poland, No. 3, p. 6

Hypnotics
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 13, 14, 15

I

Illicit traffic
Coca leaf and cocaine, No. 1, p. 25, No. 2, p. 61
Commission on Narcotic Drugs (21st session), No. 2, p. 60, 61
Hashish, No. 2, p. 1, 7, 61
Morphine, heroin, No. 1, p. 25, 26, No. 2, p. 61
Opium, No. 1, p. 27, No. 2, p. 60, 61
PCNB report (1966), No. 1, p. 23, 24, 25, 26, 27, 28

Imipramine
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 14, 16

Imports
Control
— LSD, No. 1, p. 7, 18, 19, No. 2, p. 59
— Sedatives stimulants, No. 1, p. 16, 18
PCNB report (1966), No. 1, p. 23, 24
Poland, No. 3, p. 5
Switzerland, No. 2, p. 32

India
The characteristics of opium users studied at the treatment centres in Lekhapani and North Lakhimpur, Assam, India, No. 2, p. *45-49* (ill.)
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59
History of poppy, No. 3, p. 38

Institute for the Control of Drugs, Zagreb
Determination of origin of opium, No. 3, p. 9, 10

Inter-cantonal Drug Control Convention, Switzerland
Drug control, No. 2, p. 28, 29

Inter-cantonal Drug Control Office (OICM), Switzerland
Drug control, No. 2, p. 28, 29, 30, 31, 32

International Narcotics Control Board (INCB)
Commission on Narcotic Drugs (21st session), No. 2, p. 60
PCNB report (1966), No. 1, p. 23, 24

Iran
Commission on Narcotic Drugs (21st session), No. 2, p. 59
Seminar, Teheran, No. 2, p. 60
Suppression of opium production, No. 1, p. 26

Isomethadone
Estimated world requirements, No. 1, p. 39

Israel
Commission on Narcotic Drugs (21st session), No. 2, p. 59
Seminar, Teheran, No. 2, p. 60

Italy
Commission on Narcotic Drugs (21st session), No. 2, p. 59

J

Japan
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59, 61
Illicit traffic of opium, No. 2, p. 61

Joachimoglu, G., J. Kiburis & C. Miras
Studies with the U.N. cannabis reference sample, No. 1, p. *21-22* (ill.)

"Josah"
Hashish smoking, No. 2, p. 7

K

Kath
Bibliography, No. 4, p. 48, 49

Kawa-kawa
Bibliography, No. 4, p. 48, 49

Ketobemidone
Estimated world requirements, No. 1, p. 39

Kiburis, J.; C. Miras; G. Joachimoglu & Studies with the U.N. cannabis reference sample, No. 1 p. *21-22* (ill.)

Kif, *see* Cannabis

KM blue
Variety of poppy, No. 3, p. 2, 3

Korea, Republic of
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Kritikos, P. G. & S. P. Papadaki
The history of the poppy and of opium and their expansion in antiquity in the eastern Mediterranean area, No. 3, p. *17-38* (ill.), No. 4, p. *5-10* (ill.)

Kutno Pharmaceutical Works "Polfa", Poland
Production of opium alkaloids, No. 3, p. 1, 2, 3, 4

L

Laboratories
United Nations Narcotics Laboratory, No. 1, p. 21, No. 3, p. *7-15* (ill.)
Hine Laboratories, United States, No. 2, p. 51, 55
OICM laboratory, Switzerland, No. 2, p. 29

Law enforcement
Hong Kong, No. 2, p. 35
Probation regime, parole services, No. 2, p. 39, 51
Utility of narcotics identification tests, No. 2, p. 51

Lebanon
Cannabis, No. 2, p. 7, 61
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 60

Legislation
Amphetamines, No. 1, p. 15
Egypt
— Act 182 of June 1960, No. 2, p. 6
Great Britain, No. 2, p. 36
Hong Kong
— Dangerous Drugs Ordinance, No. 2, p. 37
— Drug Addiction Treatment and Rehabilitation Ordinance, No. 2, p. 37, 40
— Mental Health Ordinance, No. 2, p. 37
India
— Assam Opium Prohibition Act, No. 2, p. 45
Medico-legal aspects of dependence on alcohol and drugs, No. 3, p. 49, 50
Switzerland, No. 2, p. 28, 31, 33
United States
— Harrison Act, No. 1, p. 24, 33

Lerner, Melvin
LSD analysis in seizures, No. 3, p. *39-45* (ill.)

Levallorphan
Identification, No. 2, p. 55, 56

Levomethorphan
Estimated world requirements, No. 1, p. 39

Levomoramide
Estimated world requirements, No. 1, p. 39

Levorphanol
Bibliography, No. 4, p. 41
Estimated world requirements, No. 1, p. 39
Poland, No. 3, p. 5

Lewis, David C.; Norman E. Zinberg & Some problems in prescribing narcotic drugs: The doctor-patient relationship, No. 1, p. *33-35*

Lorfan, *see* Levallorphan

LSD
An analysis of the problems presented in the use of LSD, No. 1, p. *7-13*
LSD analysis in seizures, No. 3, p. *39-45* (ill.)
Bibliography, No. 4, p. 48, 49, 50
Classification of psychotropic drugs, No. 1, p. 2, 3, 4, 15, 16, 17, 18, 19, No. 2, p. 14
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 61
Control in Switzerland, No. 2, p. 31, 33
Psychotherapeutic use, No. 1, p. 5, No. 2, p. 27, 28

LSD 25, *see* LSD

Lysergamide, *see* LSD

Lysergic acid diethylamide, *see* LSD

d-Lysergic acid diethylamide tartrate, *see* LSD

Lysergide, *see* LSD

M

Maconha, *see* Cannabis

Mandragora
Medicinal plant, No. 1, p. 1

Manufacture, production
Some aspects of the production, turnover and control of narcotic drugs in Poland, No. 3, p. *1-6*
Barbiturates, No. 3, p. 6
Cocaine, No. 1, p. 26, No. 2, p. 61
Codeine, dihydrocodeine, No. 1, p. 26, 27, 28, No. 3, p. 1, 4
Control
— LSD, No. 1, p. 7, 12, 17, 18, 19, No. 2, p. 59
— Sedatives, stimulants, No. 1, p. 16, 17, 18
— Switzerland, No. 2, p. 30, 31
Morphine, heroin, ethylmorphine, No. 1, p. 24, 26, 27, 28, No. 2, p. 60, 61, No. 3, p. 1, 3, 4
Opium and opium alkaloids, No. 1, p. 26, 27, 28, 37, 39, No. 2, p. 60, No. 3, p. 1, 2, 4
PCNB report (1966), No. 1, p. 23, 26, 27

Marihuana, *see* Cannabis

Measures, administrative, social & control
Amphetamines, No. 1, p. 15, 16, 17, 18, 19, No. 2, p. 33
APD (15th report), No. 1, p. 29, 31
Barbiturates, No. 1, p. 15, 17, 18, 19
LSD, No. 1, p. 15, 17, 18, 19
PCNB report (1966), No. 1, p. 24, 27, 28
Switzerland, No. 2, p. 30, 31, 33
Tranquillizers, No. 1, p. 16, 17, 18, 19

"Mecon", *see Euphorbia paralias*

Medical prescriptions
Some problems in prescribing narcotic drugs: The doctor-patient relationship, No. 1, p. *33-35*
APD (15th report), No. 1, p. 29
Commission on Narcotic Drugs, No. 2, p. 61
Control
— Psychotropic substances, No. 1, p. 15, 16, 18, No. 2, p. 31, 32, 33
— Switzerland, No. 2, p. 31, 33
Great Britain, No. 2, p. 36
Poland, No. 3, p. 5
Psychotropic substances, No. 2, p. 15

Medical profession
Some problems in prescribing narcotic drugs: The doctor-patient relationship, No. 1, p. *33-35*
Commission on Narcotic Drugs (21st session), No. 2, p. 60
Hong Kong, No. 2, p. 36
LSD, No. 1, p. 8, 12
Problem of alcoholism, No. 3, p. 48, 49, 51, 52, 54

Medical (medicinal) use
Codeine, No. 2, p. 60
Control
— LSD, No. 2, p. 59
Morphine, No. 1, p. 24, No. 3, p. 1
Opium and poppy, No. 1, p. 26, No. 2, p. 60, No. 3, p. 17, 18, 19, 21, 22, No. 4, p. 9, 10
PCNB report (1966), No. 1, p. 23
Psychotropic substances, No. 1, p. 1, 2, 3, 5, 7, 8, 9, 10, 12, 16, 17, 18, No. 2, p. 14, 15, 16, 24, 25, 26, 27, 28, 33

Medicinal plants
Psychotropic action, No. 1, p. 1, 2

Mekon (Makon)
History of opium and poppy, No. 4, p. 6

Mekonion
History of opium, No. 3, p. 21, No. 4, p. 6

Meprobamate
Classification of psychotropic drugs, No. 1, p. 2, No. 2, p. 13, 16
Poland, No. 3, p. 6
Therapeutic use, No. 2, p. 26

Mescaline
Classification of psychotropic drugs, No. 1, p. 2, 3, 10, 17, No. 2, p. 14, 17
Compared to LSD, No. 2, p. 28

Metazocine
Estimated world requirements, No. 1, p. 39

Methadone
Bibliography, No. 4, p. *39-40*
Commission on Narcotic Drugs (21st session), No. 2, p. 61
Estimated world requirements, No. 1, p. 39
Identification, No. 2, p. 51, 52, 53, 55, 56
Treatment of addicts, No. 1, p. 30, No. 2, p. 37

Methadone-Intermediate
Estimated world requirements, No. 1, p. 39

Methamphetamine
Identification, No. 2, p. 51, 52, 53, 55, 56

Methedrine, *see* Methamphetamine

Methods, *see also* Test and Determination
Studies with the U.N. cannabis reference sample, No. 1, p. *21-22* (ill.)
Extraction of opium in antiquity, No. 4, p. 6, 7
Lime, Pfeifer, Bose, Trevan, Mannich methods
— Cannabis, No. 1, p. 22
— Codeine, No. 4, p. 2
— Morphine, No. 4, p. 1, 2, 3, No. 3, p. 3
Poppy alkaloids manufacture, No. 3, p. 1, 2
Psychotherapy
— Narco., dream- and Weck analysis, No. 1, p. 5
— Technique of Desoille, No. 1, p. 8

Methyldihydromorphine
Identification, No. 2, p. 51

Methyldihydromorphinone
Estimated world requirements, No. 1, p. 39
Identification, No. 2, p. 52, 55

Methylphenobarbital
Poland, No. 3, p. 6

Metopon, *see* Methyldihydromorphinone

Mexico
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59, 61
Illicit traffic of cannabis, No. 2, p. 61
Medicinal plants, No. 1, p.1, 2

Miras, C.; G. Joachimoglu; J. Kiburis & Studies with the U.N. cannabis reference sample, No. 1, p. *21-22* (ill.)

Monoacetylmorphine
Identification of morphine, No. 2, p. 53, 55, 56

Monopoly
Opium, No. 1, p. 27, 28

Moramide-Intermediate
Estimated world requirements, No. 1, p. 39

Morphinan
Bibliography, No. 4, p. *40-41*
APD (15th report), No. 1, p. 29

Morphine
Bibliography, No. 4, p. *24-29*
The determination of morphine in opium, No. 4, p. *1-3*
APD (15th report), No. 1, p. 29
Commission on Narcotic Drugs (21st session), No. 2, p. 60, 61
Estimated world requirements, No. 1, p. 39
Identification, No. 2, p. 51, 52, 53, 54, 55, 56, 57
Obtained from poppy, No. 3, p. 1, 2, 3, 4
PCNB report (1966), No. 1, p. 24, 25, 26, 27, 28

Morphine hydrochloride
Obtained from poppy-heads, No. 3, p. 1

" Motor-Alkaloida ", Poland
Production of opium alkaloids, No. 3, p. 1

Murphy, H.B.M.; J.C. Negrete & Psychological deficit in chewers of coca leaf, No. 4, p. *11-18*

N

Nalline, *see* Nalorphine

Nalorphine
Determination of narcotics, No. 2, p. 51
Identification, No. 2, p. 51, 52, 54, 55, 56, 57
PCNB report (1966), No. 1, p. 25, 26
Treatment of addicts, No. 2, p. 40, 41

Narcotics Anonymous
Alcohol and drug dependence, No. 3, p. 52, 53

Nargileh
Hashish smoking, No. 2, p. 7

National Centre for Social and Criminological Research (NCSCR), Cairo
Hashish consumption, No. 2, p. 1, 2

National Institute of Mental Health, United States
Utility of narcotics identification tests, No. 2, p. 51

Negrete, J. C. & H. B. M. Murphy
Psychological deficit in chewers of coca leaf, No. 4, p. *11-18*

" Nepenthes "
History of poppy, No. 3, p. 18, No. 4, p. 8, 9
Tranquillizer, No. 1, p. 1

Netherlands
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Neuroleptics
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 13, 15, 16, 25

Nicocodine
Estimated world requirements, No. 1, p. 39

Nicodicodine
Estimated world requirements, No. 1, p. 39

Nicomorphine
Estimated world requirements, No. 1, p. 39

Nigeria
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Nooanaleptics, *see* Stimulants

Nooleptics, *see* Hypnotics

Norcodeine
Identification, No. 2, p. 53, 55, 56

Norcyclazocine
Identification, No. 2, p. 55, 56

Nordemerol, *see* Norpethidine

Normethadone
Estimated world requirements, No. 1, p. 39

Normorphine
Estimated world requirements, No. 1, p. 39
Identification, No. 2, p. 53, 55, 56

Norpethidine
Identification, No. 2, p. 53, 55, 56

Norpipanone
Estimated world requirements, No. 1, p. 39

Numorphan, *see* Dihydrohydroxymorphinone

O

Ololiuqui
Medicinal plant, No. 1, p. 2

Opion
History of opium, No. 4, p. 6

Opium
Bibliography, No. 4, p. *22-24*
History and expansion in antiquity in eastern Mediterranean area, No. 3, p. *17-38* (ill.), No. 4, p. *5-10* (ill.)
The characteristics of opium users studied at the treatment centres in Lekhapani and North Lakhimpur, Assam, India, No. 2, p. *45-49* (ill.)
The determination of morphine in opium, No. 4, p. *1-3*
Alkaloids obtained therefrom, No. 3, p. 1
Commission on Narcotic Drugs (21st session), No. 2, p. 60, 61
Compared to heroin, No. 2, p. 42
Estimated world requirements, No. 1, p. 37, 39
Egypt, No. 2, p. 1, 2, 8
Hong Kong, No. 2, p. 35, 40
PCNB report (1966), No. 1, p. 23, 24, 25, 26, 27, 28
Poland, No. 3, p. 4
United Nations Laboratory, No. 3, p. 7, 8, 9, 10, 11

Opium alkaloids
Bibliography, No. 4, p. *22-24*, *29-31*
Obtained from poppy, No. 3, p. 1, 2, 4

Opium eating
India, No. 2, p. 45

Opium poppy
History and expansion in antiquity in eastern Mediterranean area, No. 3, p. *17-38* (ill.), No. 4, p. *5-10* (ill.)
Bibliography, No. 4, p. 22-24
Commission on Narcotic Drugs (21st session), No. 2, p. 60
Function of poppy-heads, No. 3, p. 1, 2, 3
PCNB report (1966), No. 1, p. 26, 27, 28
Poland, No. 3, p. 2, 3

Opium smoking
Commission on Narcotic Drugs (21st session), No. 2, p. 61
Hong Kong, No. 2, p. 35
In antiquity, No. 4, p. 7, 8
PCNB report (1966), No. 1, p. 26

Oxycodone
Estimated world requirements, No. 1, p. 39
Identification, No. 2, p. 51, 52, 53, 54, 55, 56, 57
Poland, No. 3, p. 4, 5

Oxymorphone
Estimated world requirements, No. 1, p. 39

P

Pakistan
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Papadaki, S. P.; P. G. Kritikos & The history of the poppy and of opium and their expansion in antiquity in the eastern Mediterranean area, No. 3, p. *17-38* (ill.), No. 4, p. *5-10* (ill.)

Papaver
Bibliography, No. 4, p. *22-24*
History of poppy, No. 4, p. 6

Papaver hybridum
History of poppy, No. 3, p. 21

Papaver orientalis
History of poppy, No. 3, p. 21

Papaver rhoeas
History of poppy, No. 3, p. 22, 37

Papaver somniferum
History of poppy, No. 3, p. 21, 38

Papaverine
Bibliography, No. 4, p. 32, 33

Para-chlorodinitrobenzene
Determination of morphine, No. 4, p. 1, 2

" Paralion ", *see Euphorbia paralias*

Parker, K. & C. H. Hine
Manual for the determination of narcotics and dangerous drugs in the urine, No. 2, p. *51-57* (ill.)

Passion flower
Medicinal plant, No. 1, p. 1

Penalties
Assam, India, No. 2, p. 45
Hashish, No. 2, p. 1, 7

Pentazocine
Bibliography, No. 4, p. 37

Pentobarbital
Therapeutic use, No. 2, p. 24

Perazine
Poland, No. 3, p. 6

Percodan, *see* Oxycodone

Permanent Anti-Narcotics Board of the League of Arab States
Hashish consumption, No. 2, p. 7
Special Committee of Commission on Narcotic Drugs, No. 1, p. 17

Permanent Central Narcotics Board (PCNB)
Work of the PCNB in 1966, No. 1, p. *23-28*
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 17
— 21st session, No. 2, p. 60
Psychotropic substances, No. 1, p. 19
1963 report, No. 1, p. 24

Peru
Coca leaf, No. 2, p. 61
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Pervitine
Compared to LSD, No. 2, p. 28

Pethidine
Bibliography, No. 4, p. *37-39*
APD (15th report), No. 1, p. 29
Estimated world requirements, No. 1, p. 39
Identification, No. 2, p. 51, 52, 53, 55, 56

Pethidine-Intermediate-A
Estimated world requirements, No. 1, p. 39

Pethidine-Intermediate-B
Estimated world requirements, No. 1, p. 39

Pethidine-Intermediate-C
Estimated world requirements, No. 1, p. 39

Peyotl
Medicinal plant, No. 1, p. 2, 3

Pharmacology
Cannabis, No. 1, p. *21-22* (ill.)
Psychopharmacology and psychiatry — Towards a classification of psychotropic drugs, No. 1, p. *1-5*
LSD, No. 2, p. 27
Properties of poppy studied in archaeological times, No. 3, p. 17-38

" Pharmakon ", *see* " Nepenthes "

Phenadoxone
Estimated world requirements, No. 1, p. 39

Phenazocine
Estimated world requirements, No. 1, p. 39

Phenmetrazine
Poland, No. 3, p. 6

Phenobarbital
Classification of psychotropic drugs, No. 2, p. 14
Poland, No. 3, p. 6
Therapeutic use, No. 2, p. 24

Phenoperidine
Estimated world requirements, No. 1, p. 39

Phenothiazines
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 13, 15
Identification of narcotics, No. 2, p. 52, 55
Therapeutic use, No. 2, p. 25

Phenyl-aminopropane, *see* Amphetamines

Pholcodine
Estimated world requirements, No. 1, p. 39

Piminodine
Estimated world requirements, No. 1, p. 39

Piritramide
Estimated world requirements, No. 1, p. 39

Poisoning
Barbiturates, No. 2, p. 14, 15
LSD, No. 2, p. 28
Neuroleptics, No. 2, p. 15

Poland
Some aspects of the production, turnover and control of narcotic drugs in Poland, No. 3, p. *1-6*
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Poppy straw
Commission on Narcotic Drugs (21st session), No. 2, p. 60
Estimated world requirements, No. 1, p. 38
PCNB report (1966), No. 1, p. 27, 28
Poland, No. 3, p. 5
Production of alkaloids, No. 3, p. 4

Portugal
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Potassium hydroxide
Identification of narcotics, No. 2, p. 52, 53, 54

Production, *see* Manufacture

Prohibition
Alcohol, No. 3, p. 48
Assam, India, No. 2, p. 45, 48
Egypt, No. 2, p. 6
Hashish, No. 2, p. 1, 3
Hong Kong, No. 2, p. 38, 42
Opium and poppy, No. 1, p. 26, 27, No. 2, p. 35, 38
Psychotropic substances, No. 2, p. 31

Properidine
Estimated world requirements, No. 1, p. 39

D-propoxyphene
Identification, No. 2, p. 51, 52, 55, 56

1953 Protocol
Opium, No. 1, p. 27

Psilocin
Classification of psychotropic drugs, No. 2, p. 17

Psilocybin
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 14, 17
Control in Switzerland, No. 2, p. 31
Used in psychotherapy, No. 1, p. 5

Psychedelic drugs
LSD, No. 1, p. 10, 11, 12

Psychiatry
Psychopharmacology and psychiatry — Towards a classification of psychotropic drugs, No. 1, p. *1-5*
LSD, No. 1, p. 7, 8, 9, No. 2, p. 27

Psychoanaleptics
Psychotropic action, No. 1, p. 2, 3, No. 2, p. 13, 14, 16, 26, 27

Psychodysleptics
Psychotropic action, No. 1, p. 2, 3, 4, No. 2, p. 13, 14, 16, 17, 27, 28

Psycholeptics
Psychotropic action, No. 1, p. 2, 3, No. 2, p. 13, 14, 15, 16, 24, 25, 26

Psychotropic drugs
LSD, No. 1, p. *7-13*, 15
Psychopharmacology and psychiatry — Towards a classification of psychotropic drugs, No. 1, p. *1-5*
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
APD (15th report), No. 1, p. 31
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 60, 61
International control, No. 1, p. 15
United Nations Laboratory, No. 3, p. 14, 15

Pui Sun Association, Hong Kong
Rehabilitation of addicts, No. 2, p. 41, 42

Pulawy blue
Variety of poppy, No. 3, p. 2

Pulawy white
Variety of poppy, No. 3, p. 2

Q

Quinine
Identification, No. 2, p. 55, 56

R

Racemoramide
Estimated world requirements, No. 1, p. 39

Rauwolfia alkaloids
Classification of psychotropic drugs, No. 2, p. 13, 15
Therapeutic use, No. 2, p. 25

Rauwolfia serpentina
Medicinal plant, No. 1, p. 1

Raw materials
Opium and poppy, No. 1, p. 27, 28, No. 2, p. 60, No. 3, p. 1, 3, 4

Recommendations
APD
— Sedatives, stimulants, No. 1, p. 15, 16
Commission on Narcotic Drugs
— Psychotropic substances, No. 1, p. 7, 15, 16, 17, 18, 19
Opium research, No. 3, p. 8
WHO Expert Committee on Mental Health (14th report), No. 3, p. 54, 55

Rehabilitation, *see* Treatment

Research
Cannabis, No. 3, p. 12, 13, 14
Heroin, No. 3, p. 14
Opium, No. 3, p. 7, 8, 9, 10, 11

Reserpine
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 13, 15, 26
Poland, No. 3, p. 6

Resolutions
Commission on Narcotic Drugs
— LSD, No. 1, p. 7, 19
— IV, No. 1, p. 16
— VI, No. 1, p. 15
— VII, No. 1, p. 16
— 4 (XVII), No. 1, p. 15
Council
— UN opium research programme, No. 3, p. 7
— 49 (IV), No. 3, p. 14
— 1196 (XLII), No. 2, p. 60
— 1197 (XLII), No. 2, p. 59
General Assembly
— 834 (IX), No. 3, p. 7
World Health Assembly
— Psychotropic substances, No. 1, p. 16, 17

S

Samples
Studies with the U.N. cannabis reference sample, No. 1, p. *21-22* (ill.)
Research
— Cannabis, No. 3, p. 12
— Opium, No. 3, p. 8, 9, 11, No. 4, p. 1, 2, 3

Secobarbital
Therapeutic use, No. 2, p. 24

Sedatives, *see also* Tranquillizers and Barbiturates
International control, No. 1, p. 16, 17, 18
PCNB report (1966), No. 1, p. 26

Seizures
LSD analysis in seizures, No. 3, p. *39-45* (ill.)
Cocaine, No. 2, p. 2, 61
Egypt, No. 2, p. 1, 2
Hashish, No. 2, p. 2, 7
Heroin, No. 2, p. 2
Methadone, No. 2, p. 61
Opium, No. 2, p. 2

Seminars, Study Tours
Seminar for the training of enforcement officers in the Middle East, No. 2, p. 60
Study Tour in Latin America (coca leaf, cocaine), No. 2, p. 60

Society for the Aid and Rehabilitation of Drug Addicts, Hong Kong
Treatment of addicts, No. 2, p. 42

Soueif, M. I.
Hashish consumption in Egypt, with special reference to psychosocial aspects, No. 2, p. *1-12* (ill.)

Spain
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Statistics, estimates
Estimated world requirements, No. 1, p. *37-39*
Addiction in Hong Kong, No. 2, p. 35
PCNB report (1966), No. 1, p. 23, 25
Studies on abstinence, No. 2, p. 41

Stimulants, *see also* Amphetamines
Classification of psychotropic drugs, No. 1, p. 2, 3, No. 2, p. 14, 16, 26, 27
Commission on Narcotic Drugs (21st session), No. 2, p. 59
International control, No. 1, p. 16, 17, 18
PCNB report (1966), No. 1, p. 26

Stocks
Psychotropic substances, No. 1, p. 17

Sweden
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Switzerland
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Synanon Houses, USA
Rehabilitation of addicts, No. 2, p. 43

Synthetic narcotic drugs
Commission on Narcotic Drugs (21st session), No. 2, p. 60
PCNB report (1966), No. 1, p. 25, 27
United Nations Laboratory, No. 3, p. 14, 15

T

Taylor, G. C.
An analysis of the problems presented in the use of LSD, No. 1, p. *7-13*

Technical assistance
Commission on Narcotic Drugs (21st session), No. 2, p. 60
United Nations Laboratory, No. 3, p. 14, 15

Teonanacatl
Medicinal plant, No. 1, p. 2

Test, *see also* Methods
Acid hydrolysis, No. 2, p. 51, 52
Control in Switzerland, No. 2, p. 30
Reagents, reactions
— Beam, Ghamravy, Duquénois-Negm, No. 3, p. 12
— Dragendorff, No. 2, p. 55, 56
— Phenol, No. 2, p. 54
Thin-layer, gas, gas-liquid chromatography
— Cannabis, No. 1, p. 21, 22, No. 3, p. 13
— LSD, No. 3, p. 40, 41, 42, 43, 44, 45
— Narcotics, No. 2, p. 51, 52
Ultra-violet and infra-red spectroscopy, direct and ultra-violet absorption spectrophotometry, colour reactions, spectrophoto-fluorometric method
— Cannabis, No. 1, p. 21, 22, No. 3, p. 13
— LSD, No. 3, p. 41, 42
— Opium, No. 3, p. 9, 10, 11
Urine analysis
— Determination of narcotics, No. 2, p. 51, 53

Thailand
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 60

Thebacon
Estimated world requirements, No. 1, p. 39

Thebaine
Bibliography, No. 4, p. 32, 33
Estimated world requirements, No. 1, p. 39

Thioridazine
Poland, No. 3, p. 6

Thymoanaleptics, *see* Stimulants

Thymoleptics, *see* Neuroleptics

Tolerance, *see* Addiction

Toxicity, *see* Poisoning

Trade
Poland, No. 3, p. 4, 5
PCNB report (1966), No. 1, p. 26
Switzerland, No. 2, p. 31
United States, No. 1, p. 24

Tranquillizers
The barbiturates, tranquillizers, amphetamines and hallucinogens and their control in Switzerland, No. 2, p. *13-34*
The road to controls: barbiturates, amphetamines, tranquillizers and hallucinogens, No. 1, p. *15-19*
Classification of psychotropic drugs, No. 1, p. 2, 3, 5
Commission on Narcotic Drugs (21st session), No. 2, p. 59, 61
PCNB report (1966), No. 1, p. 27
Poland, No. 3, p. 6

Treatment
Lessons from the Anti-Narcotic Voluntary Treatment Programme in Hong Kong, No. 2, p. *35-43* (ill.)
Services for the prevention and treatment of dependence on alcohol and other drugs — 14th report of WHO Expert Committee on Mental Health, No. 3, p. *47-55*
Some problems in prescribing narcotic drugs: The doctor-patient relationship, No. 1, p. *33-35*
The characteristics of opium users studied at the treatment centres in Lekhapani and North Lakhimpur, Assam, India, No. 2, p. *45-49* (ill.)
APD (15th report), No. 1, p. 29, 30
Commission on Narcotic Drugs (21st session), No. 2, p. 61
PCNB report (1966), No. 1, p. 24, 28

Trimeperidine
Estimated world requirements, No. 1, p. 39

Tunisia
Commission on Narcotic Drugs (21st session), No. 2, p. 59

Turkey
Commission on Narcotic Drugs (21st session), No. 2, p. 59
Seminar, Teheran, No. 2, p. 60

U

Union of Soviet Socialist Republics (USSR)
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59
Drug control, No. 2, p. 30

United Arab Republic (UAR)
Hashish consumption in Egypt, with special reference to psychosocial aspects, No. 2, p. *1-12* (ill.)
Cannabis, No. 2, p. 61
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59
History of poppy, No. 3, p. 26, 28, 36, 37

United Kingdom
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 21st session, No. 2, p. 59
Drug control, No. 2, p. 30

United States of America
Alcohol dependence, No. 3, p. 50
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 7, 17
— 20th session, No. 2, p. 60
— 21st session, No. 2, p. 59
Drug control, No. 2, p. 30
Law enforcement services, No. 2, p. 51
LSD, No. 1, p. 7
PCNB report (1966), No. 1, p. 24, 25

Use and abuse, *see* Addiction

W

Withdrawal, abstinence
APD (15th report), No. 1, p. 29, 30
Commission on Narcotic Drugs (21st session), No. 2, p. 61
LSD, No. 3, p. 40
Syndrome
— Alcohol, No. 3, p. 48
— Barbiturates, No. 2, p. 14, No. 3, p. 48
— Definition of addiction, No. 1, p. 33, No. 2, p. 26
— Hashish, No. 2, p. 9
— Tranquillizers, No. 1, p. 16
Treatment, No. 2, p. 36, 37, 40, 42, No. 3, p. 52

World Health Organization (WHO)
Expert Committee on Mental Health (14th report), No. 3, p. *47-55*
APD
— Fifteenth Report, No. 1, p. *29-32*
— Amphetamines, No. 1, p. 15
— Barbiturates, No. 1, p. 15
— Drug abuse, No. 2, p. 7
— Hallucinogens, No. 1, p. 17
— Tranquillizers, No. 1, p. 16
Commission on Narcotic Drugs
— Special Committee, No. 1, p. 17, 18, 19
— 21st session, No. 2, p. 61
Definition of addiction, No. 1, p. 33, No. 2, p. 13
Problem of LSD and other psychotropic substances, No. 1, p. 12, 16, 17, 18, 19
Treatment, No. 2, p. 36
United Nations Laboratory, No. 3, p. 15

Y

Yap, Pow Meng
Lessons from the Anti-Narcotic Voluntary Treatment Programme in Hong Kong, No. 2, p. *35-43* (ill.)

Yugoslavia
Commission on Narcotic Drugs (21st session), No. 2, p. 59
Opium production, No. 3, p. 1

Z

Zinberg, Norman E. & David C. Lewis
Some problems in prescribing narcotic drugs: The doctor-patient relationship, No. 1, p. *33-35*